Interview: BioLineRx Pushes Ahead In Pancreatic Cancer
Combo of BL-8040, Keytruda And Chemo Shows Promise
Executive Summary
The Israeli group is confident that its CXCR4 antagonist has potential as a platform molecule for a range of cancers at various stages of disease.
You may also be interested in...
Vifor Confident About Prospects For Pruritus Dialysis Drug Korsuva
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.
SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy
A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.
Aimmune's Peanut Immunotherapy Palforzia Gets CHMP Backing
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.
Need a specific report? 1000+ reports available
Buy Reports